Q32 Bio (QTTB) Stock
Biotech company developing gene therapies for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Q32 Bio in July 2026.
Homology Medicines Inc (QTTB) is a small-cap biotechnology company focused on developing gene editing and gene therapy approaches for rare genetic diseases. With a market capitalisation around $36.2 million, it is an early-stage developer: clinical data, regulatory milestones, partnerships and financing will be the main drivers of value. Investors should expect high volatility, potential dilution from future fundraising and long timelines typical of biotech development. Key areas to watch include cash runway, trial results, intellectual property position and competitor activity in similar gene therapies. The company’s prospects hinge on scientific validation and regulatory approvals — outcomes that are inherently uncertain. This summary is general, educational information only and not personalised investment advice; values can rise or fall and past performance is not a reliable indicator of future returns. Consider your risk tolerance and seek independent financial advice before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Homology Medicines' stock with a target price of $16.25, indicating strong growth potential.
Financial Health
Homology Medicines is showing reasonable financial performance, but there are areas that need improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring QTTB
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketBiotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketHematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: 30 August 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: 19 August 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage gene platform
Focuses on gene editing and therapy programmes; scientific validation can materially affect valuation, though outcomes are uncertain.
Data drives value
Clinical readouts, regulatory steps and partnerships tend to move the share price; investors should expect volatility and binary outcomes.
Balance risk and reward
Small market capitalisation and limited resources create upside and downside potential; consider runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
